Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 8;7:379. doi: 10.1038/s41420-021-00715-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A Western blot assay of the expression and quantitative analysis of KEAP1 in A2780 and A2780/DDP cells overexpressing OGT normalized to β-actin. B Co-IP assay of the interaction between OGT and KEAP1 in A2780 cells or A2780/DDP cells. C Co-IP assay of KEAP1 glycosylation in A2780 cells or A2780/DDP cells. D Co-IP assay of the ubiquitination modification level of NRF2 in A2780 cells or A2780/DDP cells. E Western blot assay of changes in KEAP1 glycosylation in A2780 cells or A2780/DDP cells. F Co-IP assay of the ubiquitination degree of NRF2 in A2780 cells or A2780/DDP cells. A2780/DDP cells were treated with oe-NC + sh-NC, oe-OGT, oe-OGT + sh-KEAP1 or oe-OGT + oe-NRF2. G Western blot assay of the expression and quantitative analysis of OGT, KEAP1, and NRF2 in A2780/DDP cells normalized to β-actin. H CCK-8 assay of the change of A2780/DDP cell viability. I Western blot assay of cleaved caspase-3 expression and quantitative analysis in A2780/DDP cells normalized to β-actin. J Western blot assay of PCNA expression and quantitative analysis in A2780/DDP cells normalized to β-actin. A2780 cells were treated with oe-NC + sh-NC, sh-OGT, sh-OGT + oe-KEAP1 or sh-OGT + sh-NRF2. K Western blot assay determination of KEAP1, OGT, and NRF2 expression and quantitative analysis in A2780 cells normalized to β-actin. L CCK-8 assay assessment of A2780 cell viability. M Western blot assay of the cleaved caspase-3 expression and quantitative analysis in A2780 cells normalized to β-actin. N Western blot assay of PCNA expression and quantitative analysis in A2780 cells normalized to β-actin. Cell experiments were repeated three times independently. *p < 0.05 versus A2780/DDP or A2780 cells treated with oe-NC, A2780/DDP or A2780 cells treated with sh-NC or A2780/DDP or A2780 cells treated with oe-NC + sh-NC. #p < 0.05 versus A2780/DDP cells treated with oe-OGT or A2780 cells treated with sh-OGT.